Kevzara Market Report 2026

Kevzara Market Overview

• The Kevzara market growth in the historic period has been driven by high rheumatoid arthritis prevalence, limitations of conventional dmards • Market expansion is supported by increasing autoimmune disease burden, expansion into additional inflammatory indications • Growth Driver: Impact Of Increasing Rheumatoid Arthritis Prevalence On The Growth Of The Market • Market Trend: Advancements In IL-6 Receptor Blocker Therapies For Inflammatory Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Kevzara Market?

Kevzara is a prescription biologic medication classified as a monoclonal antibody, designed to treat moderate to severe rheumatoid arthritis (RA) in adults. It works by targeting and inhibiting interleukin-6 (IL-6), a protein that plays a key role in inflammation. By blocking IL-6 receptors, Kevzara helps to reduce inflammation and alleviate symptoms associated with RA. In addition to RA, Kevzara may also be used to treat other inflammatory conditions as prescribed by healthcare professionals. The main formulations of kevzara are injectable formulations and autoinjectors. Injectable formulations deliver biological therapies directly into the bloodstream via injection, ensuring controlled release and effective treatment for chronic conditions such as rheumatoid arthritis. It is applicable in various indications, such as treatment of moderate to severe rheumatoid arthritis, treatment of giant cell arteritis, and others, and is used for various patient demographics, including pediatric patients, adult patients, and geriatric patients. It is distributed by several distribution channels, such as direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, and used by various end users, including hospitals, specialty clinics, outpatient treatment centers, and home healthcare providers.

What Is The Kevzara Market Growth Forecast?

The growth in the forecast period can be attributed to increasing autoimmune disease burden, expansion into additional inflammatory indications, rising biologic acceptance, improved access to specialty care, innovation in cytokine targeting. Major trends in the forecast period include rising adoption of il 6 inhibitors, growth in biologic ra treatments, expansion of targeted anti inflammatory therapies, preference for injectable biologics, focus on long term disease control.

Global Kevzara Market Segmentation

1) By Formulation: Injectable Formulation, Autoinjectors 2) By Indication: Treatment Of Moderate To Severe Rheumatoid Arthritis, Treatment Of Giant Cell Arteritis, Other Potential Indications 3) By Patient Demographic: Pediatric Patients, Adult Patients, Geriatric Patients 4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies 5) By End-User: Hospitals, Specialty Clinics, Outpatient Treatment Centers, Home Healthcare Providers

What Are The Drivers Of The Kevzara Market?

The increasing prevalence of rheumatoid arthritis (RA) will significantly drive the growth of the kevzara market in the future. Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects the joints, causing inflammation, pain, swelling, and stiffness. The prevalence of rheumatoid arthritis (RA) can be attributed to several factors, including genetic predisposition, environmental triggers, hormonal influences, and immune system dysfunction. Kevzara manages RA symptoms by specifically blocking IL-6, a protein that drives inflammation. This helps reduce inflammation, improve joint health, and enhance the overall quality of life for individuals living with the condition. For instance, in February 2024, according to the Arthritis Australia, an Australia-based government agency, the number of Australians with arthritis is projected to rise from 4.11 million in 2025 to 5.39 million by 2040. Over the same period, cases of osteoarthritis are expected to increase from 2.35 million to 3.11 million, while the number of people living with rheumatoid arthritis is forecast to reach 748,721 by 2040. Therefore, the increasing prevalence of rheumatoid arthritis (RA) is driving the growth of the Kevzara industry. The rise in healthcare expenditure is expected to propel the growth of the kevzara market going forward. Healthcare expenditure refers to the total amount of financial resources allocated for healthcare services and products within a country or region. Several factors drive healthcare expenditure, including an aging population, advances in medical technology, rising healthcare prices, a focus on preventive care, and expansion of health insurance coverage. Kevzara, as an expensive biologic treatment for rheumatoid arthritis and other inflammatory conditions, requires ongoing administration, leading to long-term treatment costs. Its high price contributes significantly to overall healthcare expenditure for both patients and healthcare systems. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, the rise in healthcare expenditure is driving the growth of the kevzara industry.

Key Players In The Global Kevzara Market

Major companies operating in the kevzara market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

Global Kevzara Market Trends and Insights

The key trend in the kevzara market is developing advanced products such as interleukin-6 (IL-6) receptor blocker medicine to expand the therapeutic applications for inflammatory disorders. An interleukin-6 (IL-6) receptor blocker medicine is a biological drug that targets and blocks IL-6, a protein driving inflammation. It helps reduce inflammation and treat conditions such as rheumatoid arthritis. For instance, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, and Sanofi, a France-based healthcare company, announced that the U.S. Food and Drug Administration (FDA) approved Kevzara (sarilumab) for treating polymyalgia rheumatica (PMR), an inflammatory rheumatic condition, in adults who have not responded well to corticosteroids or who cannot tolerate a reduction in their corticosteroid dosage. Kevzara acts as an IL-6 receptor blocker to help reduce inflammation and disease activity. It is administered via subcutaneous injection and provides an alternative to long-term steroid use. The medication has demonstrated significant efficacy in achieving sustained remission in PMR patients and in reducing their dependence on corticosteroids.

Regional Insights

North America was the largest region in the kevzara market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Kevzara Market?

The kevzara market consists of sales of subcutaneous injections, pre-filled syringes, and pre-filled pens. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Kevzara Market Report 2026?

The kevzara market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the kevzara industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.